Akelos, Inc. filed a Form D with the Securities and Exchange Commission on 2026-03-16.
Akelos, Inc. filed a Form D notice of an exempt securities offering with the SEC on March 16, 2026. The filing reports $1.49M sold. Its industry group is Biotechnology. It names Steven Fox (Executive Officer) (SEC Form D, March 16, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Akelos, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-03-16 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Akelos, Inc.
Free to see. No signup.
More on the people and the money behind Akelos, Inc., from the filings we hold.
Biotechnology raises by companies based in New York, filed within 90 days of this one, largest first.
Get an email when Akelos, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Akelos, Inc. raises, hires or launches. No email unless you switch it on.
Watch Akelos, Inc. →Get the full cited report on Akelos, Inc.
What the filing shows about Akelos, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Akelos, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Akelos, Inc.'s address as 215 East 68TH Street, Suite 26B, New York, NY 10065.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Akelos, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Akelos, Inc. is a registered filer with the SEC (CIK 1760186) and has filed since 2018-11-28. 4 filings are on record, the latest on 2026-03-16.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Akelos, Inc.'s Form D of 2026-03-16 names Steven Fox as its officers, directors or promoters.
Its new offerings report $1.82M sold across 4 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $1.49M, on the same scale — one filing against the whole group's total, so it sits low by construction.
By form type: D ×4.
What the filing shows about Akelos, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Akelos, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Akelos, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The 4 most recent of 4 filings on CIK 0001760186, filed as Akelos, Inc.. Read from the SEC's own submissions feed for this issuer, not from a third party. Incorporated in DE. Full history on sec.gov.
Steven Fox is named as Executive Officer on the Form D that Akelos, Inc. filed with the SEC on 16 March 2026, the only person that filing names.
1 person named on the filing — 1 holding an executive role.
Named as of the 2026-03-16 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Akelos, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Akelos, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Akelos, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in New York
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/akelos-inc-form-d-26000001